Concepts and targets in triple-negative breast cancer: Recent results and clinical implications

Therapeutic Advances in Medical Oncology

Volumn 8, Issue 5, 2016, Pages 351-359

  Saha, Poornima ^a   Nanda, Rita ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

targeted therapy; therapeutic targets in triple negative breast cancer; triple negative breast cancer

Indexed keywords

ANDROGEN RECEPTOR ANTAGONIST; ANTHRACYCLINE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; ATEZOLIZUMAB; AVELUMAB; BEVACIZUMAB; BICALUTAMIDE; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ENZALUTAMIDE; GLEMBATUMUMAB; GLEMBATUMUMAB VEDOTIN; GLUCOCORTICOID RECEPTOR ANTAGONIST; IMMUNE CHECKPOINT INHIBITOR; MIFEPRISTONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PACLITAXEL; PEMBROLIZUMAB; PLATINUM; SACITUZUMAB GOVITECAN; TAXANE DERIVATIVE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VELIPARIB;

HUMAN; PRIORITY JOURNAL; REVIEW; TRIPLE NEGATIVE BREAST CANCER;

EID: 84981356506     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834016657071     Document Type: Review

References (45)

1. Adams S., Diamond J., Hamilton E., Pohlmann P., Tolaney S., Molinero L., et al. (2015) Safety and clinical activity of atezolizumab (anti-PDL1) in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer. Poster presented at San Antonio Breast Cancer Symposium, 8-12 December 2015, San Antonio, TX, USA.
2. Ambrogi F., Fornili M., Boracchi P., Trerotola M., Relli V., Simeone P., et al. (2014) Trop-2 is a determinant of breast cancer survival. PLoS One 9: e96993.
3. Bardia A., Diamond J., Mayer I., Starodub A., Moroose R., Isakoff S., et al. (2015) Safety and efficacy of anti-Trop-2 antibody drug conjugate, sacituzumab govitecan (IMMU-132), in heavily pretreated patients with TNBC. Poster presented at San Antonio Breast Cancer Symposium, 8-12 December 2015, San Antonio, TX, USA.
4. Bendell J., Saleh M., Rose A., Siegel P., Hart L., Sirpal S., et al. (2014) Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer. J Clin Oncol 32: 3619-3625.
5. Byrski T., Gronwald J., Huzarski T., Grzybowska E., Budryk M., Stawicka M., et al. (2010) Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28: 375-379.
6. Cardillo T., Govindan S., Sharkey R., Trisal P., Arrojo R., Liu D., et al. (2015) Sacituzumab govitecan (Immu-132), an anti-Trop-2/Sn-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers. Bioconjug Chem 26: 919-931.
7. Carey L., Perou C., Livasy C., Dressler L., Cowan D., Conway K., et al. (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295: 2492-2502.
8. Chen D., Mellman I., (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39: 1-10.
9. Choi J., Kang S., Lee S., Bae Y., (2015) Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer. Ann Surg Oncol 22: 82-89.
10. Coleman R., Sill M., Bell-Mcguinn K., Aghajanian C., Gray H., Tewari K., et al. (2015) A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol 137: 386-391.
11. Dirix L., Takacs I., Nikolinakos P., Jerusalem G., Arkenau HT., Hamilton E., et al. (2015) Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase Ib Javelin Solid Tumor Trial. Abstract presented at San Antonio Breast Cancer Symposium, 8-12 December 2015, San Antonio, TX, USA.
12. Emens L., Braiteh F., Cassier P., DeLord J-P., Eder J., Shen X., et al. (2014) Inhibition of PD-L1 by MPDL3280a leads to clinical activity in patients with metastatic triple-negative breast cancer. Abstract presented at San Antonio Breast Cancer Symposium, 9-13 December 2014, San Antonio, TX, USA.
13. Goldenberg D., Cardillo T., Govindan S., Rossi E., Sharkey R., (2015a) Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (Immu-132), an antibody-drug conjugate (ADC). Oncotarget 6: 22496-22512.
14. Goldenberg D., Cardillo T., Govindan S., Zalath M., Arrojo R., Sharkey R., (2015b) Synthetic lethality in TNBC mediated by an anti-Trop-2 antibody-drug conjugate, sacituzumab govitecan (IMMU-132), when combined with paclitaxel or the PARP inhibitor, olaparib. Abstract presented at San Antonio Breast Cancer Symposium 2015, 8-12 December 2015, San Antonio, TX, USA.
15. Gucalp A., Tolaney S., Isakoff S., Ingle J., Liu M., Carey L., et al. (2013) Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res 19: 5505-5512.
16. Hartman A., Kaldate R., Sailer L., Painter L., Grier C., Endsley R., et al. (2012) Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer 118: 2787-2795.
17. Isakoff S., Overmoyer B., Tung N., Gelman R., Giranda V., Bernhard K., et al. (2010) A phase II trial of the PARP inhibitor veliparib (Abt888) and temozolomide for metastatic breast cancer. J Clin Oncol 28: 1019.
18. Kaufman B., Shapira-Frommer R., Schmutzler R., Audeh M., Friedlander M., Balmana J., et al. (2015) Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 33: 244-250.
19. Lehmann B., Bauer J., Chen X., Sanders M., Chakravarthy A., Shyr Y., et al. (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121: 2750-2767.
20. Loi S., Michiels S., Salgado R., Sirtaine N., Jose V., Fumagalli D., et al. (2014) Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 25: 1544-1550.
21. Loibl S., Muller B., Von Minckwitz G., Schwabe M., Roller M., Darb-Esfahani S., et al. (2011) Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 130: 477-487.
22. Masuda H., Baggerly K., Wang Y., Zhang Y., Gonzalez-Angulo A., Meric-Bernstam F., et al. (2013) Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res 19: 5533-5540.
23. Mayer I., Abramson V., Lehmann B., Pietenpol J., (2014) New strategies for triple-negative breast cancer: deciphering the heterogeneity. Clin Cancer Res 20: 782-790.
24. Mikosz C., Brickley D., Sharkey M., Moran T., Conzen S., (2001) Glucocorticoid receptor-mediated protection from apoptosis is associated with induction of the serine/threonine survival kinase gene, Sgk-1. J Biol Chem 276: 16649-16654.
25. Nanda R., Chennamaneni P., Stringer E., Khramtsova G., Gibson J., Libao B., et al. (2013) A randomized phase I trial of nanoparticle albumin bound paclitaxel (Abraxane®) with or without mifepristone for advanced breast cancer. Poster presented at San Antonio Breast Cancer Symposium (SABCS), December 2013, San Antonio, TX, USA.
26. Nanda R., Chow L., Dees E., Berger R., Gupta S., Geva R., et al. (2016) Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib Keynote-012 Study. J Clin Oncol 34: JCO648931.
27. National Cancer Institute Surveillance Epidemiology, and End Results Program. Available at: http://seer.cancer.gov/statfacts/html/breast.html (. accessed 16 June 2016).
28. Niemeier L., Dabbs D., Beriwal S., Striebel J., Bhargava R., (2010) Androgen receptor in breast cancer: Expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol 23: 205-212.
29. Pan D., Kocherginsky M., Conzen S., (2011) Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer. Cancer Res 71: 6360-6370.
30. Perou C., Sorlie T., Eisen M., van de Rijn M., Jeffrey S., Rees C., et al. (2010) Molecular portraits of human breast tumours. Nature 406: 747-752.
31. Rose A., Grosset A., Dong Z., Russo C., Macdonald P., Bertos N., et al. (2010) Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer. Clin Cancer Res 16: 2147-2156.
32. Rugo H., Olopade O., DeMichele A., Veer L., Buxton M., Hylton N., et al. (2013) Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: first efficacy results from the I-SPY 2 Trial. Abstract presented at 2013 San Antonio Breast Cancer Symposium, 13 December 2013, San Antonio, TX, USA.
33. Sharkey R., Mcbride W., Cardillo T., Govindan S., Wang Y., Rossi E., et al. (2015) Enhanced delivery of Sn-38 to human tumor xenografts with an anti-Trop-2-Sn-38 antibody conjugate (sacituzumab govitecan). Clin Cancer Res 21: 5131-5138.
34. Sikov W., Berry D., Perou C., Singh B., Cirrincione C., Tolaney S., et al. (2015) Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: Calgb 40603 (Alliance). J Clin Oncol 33: 13-21. Originally presented at SABCS then published in JCO 2015.
35. Silver D., Richardson A., Eklund A., Wang Z., Szallasi Z., Li Q., et al. (2010) Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 28: 1145-1153.
36. Skor M., Wonder E., Kocherginsky M., Goyal A., Hall B., Cai Y., et al. (2013) Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer. Clin Cancer Res 19: 6163-6172.
37. Starodub A., Ocean A., Shah M., Guarino M., Picozzi V. Jr, Vahdat L., et al. (2015) First-in-human trial of a novel anti-Trop-2 antibody-Sn-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors. Clin Cancer Res 21: 3870-3878.
38. Stringer-Reasor E., Baker G., Skor M., Kocherginsky M., Lengyel E., Fleming G., et al. (2015) Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma. Gynecol Oncol 138: 656-662.
39. Traina T., O'Shaughnessy J., Nanda R., Schwartzberg L., Abramson V., Cortes J., et al. (2014) Stage 1 results from MDV3100-1: a 2-stage study fo enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC). Abstract presented at San Antonio Breast Cancer Symposium, 9-13 December 2014, San Antonio, TX, USA.
40. Tutt A., Ellis P., Kilburn L., Gilett C., Pinder S., Abraham J., et al. (2014) TNT: a randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA 1/2 breast cancer. Abstract Presented at 37th Annual San Antonio Breast Cancer Symposium, 9-13 December 2014, San Antonio, TX, USA.
41. Tutt A., Robson M., Garber J., Domchek S., Audeh M., Weitzel J., et al. (2010) Oral poly(adp-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376: 235-244.
42. Von Minckwitz G., Loibl S., Schneeweiss A., Salat C., Rezai M., Zahm D-M., et al. (2015) Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (Geparsixto). Abstract presented at 2015 San Antonio Breast Cancer Symposium, 9 December 2015, San Antonio, TX, USA.
43. Von Minckwitz G., Schneeweiss A., Loibl S., Salat C., Denkert C., Rezai M., et al. (2014) Neoadjuvant carboplatin in patients with triple-negative and Her2-positive early breast cancer (Geparsixto; Gbg 66): a randomised phase 2 trial. Lancet Oncol 15: 747-756.
44. Wang Y., Waters J., Leung M., Unruh A., Roh W., Shi X., et al. (2014) Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 512: 155-160.
45. Yardley D., Weaver R., Melisko M., Saleh M., Arena F., Forero A., et al. (2015) EMERGE: a randomized phase II study of the antibody-drug conjugate glembatumumab vedotin in advanced glycoprotein-NMB expressing breast cancer. J Clin Oncol 33: 1609-1619.